NEW YORK – Inivata said on Thursday that it has raised $35 million in a second close of a Series C financing round.
The Cambridge, UK-based firm will use the funds to accelerate clinical development and continued rollout of its RaDaR minimal residual disease (MRD) detection and recurrence assay.